Skip to main content

Table 4 Results of the TSQM surveys

From: Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study

Items

Visit 2 (n attacks = 43)

Visit 3 (n attacks = 62)

Visit 4 (n attacks = 84)

Total (n attacks = 189)

Effectiveness (median; IQR)

67 (56–69)

56 (50–72)

67 (50–79)

67 (50–78)

Side effects (median; IQR)

100 (63–100)

100 (100–100)

100 (100–100)

100 (100–100)

• Number of attacks with side effects

16 (37%)

15 (24%)

11 (13%)

42 (22%)

Convenience (median; IQR)

50 (44–56)

50 (44–54)

50 (44–50)

50 (44–56)

Global satisfaction (median; IQR)

53 (46–69)

63 (61–69)

73 (53–85)

63 (53–83)

  1. Scores range from 0 (extremely negative) to 100 (extremely positive) for each item